4D Pharma PLC ADR (LBPS) Peer Comparison

$1.65

$0.00 (0.00%)

As on 28-Jul-2022 09:30EDT

Market cap

$37 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

1.3

Div. Yield

0 %

Edit

	4D Pharma PLC ADR (LBPS)	Silence Therapeutics PLC (SLN)	OKYO Pharma Ltd ADR (OKYO)
Market cap ($ Mln)	37	825	81
Revenue (£ Mln)	1	1	--
Net Profit (£ Mln)	-31.94	-59.93	-8.95
Net Margin (%)	--	-9,755.61	--
RoE (%)	-105.78	-118.93	-263.80
Price to Earnings	--	--	--
Price-To-Book	1.32	21.30	6.38

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (£ Mln)

	4D Pharma PLC ADR (LBPS)	Silence Therapeutics PLC (SLN)	OKYO Pharma Ltd ADR (OKYO)
Operating Revenue	0.72	12.42	0.00
Cost of Revenue	--	7.46	0.81
Gross Profit	--	4.96	-0.81
Operating Expenses	37.52	50.77	3.32
Operating Profit (EBIT)	-37.26	-45.81	-4.13
Other Income	--	--	--
Profit before Tax	-31.96	-45.86	-3.38
Provision for Tax	-0.02	-6.45	-0.03
Profit after Tax (Net Income)	-31.94	-39.41	-3.35
Minority Interest	--	--	--
Consolidated Profit	-31.94	-39.41	-3.00

Liabilities (£ Mln)

	4D Pharma PLC ADR (LBPS)	Silence Therapeutics PLC (SLN)	OKYO Pharma Ltd ADR (OKYO)
Shareholder's Funds	32.42	8.53	5.32
Minority Interest	--	--	--
Non-Current Liabilities	19.76	72.50	0.06
Current Liabilities	6.62	15.17	1.71
Total Liabilities	58.79	96.19	7.09

Assets (£ Mln)

	4D Pharma PLC ADR (LBPS)	Silence Therapeutics PLC (SLN)	OKYO Pharma Ltd ADR (OKYO)
Non-Current Assets	24.29	9.86	0.10
Current Assets	34.50	86.33	6.99
Total Assets	58.79	96.19	7.09
Total Debt*	12.80	0.14	0.10
Net Current Assets	27.88	71.17	3.83

Cashflow (£ Mln)

	4D Pharma PLC ADR (LBPS)	Silence Therapeutics PLC (SLN)	OKYO Pharma Ltd ADR (OKYO)
Cash From Operating Activities	-37.92	9.19	-1.60
Cash Flow from Investing Activities	-0.28	11.71	-0.02
Cash from Financing Activities	46.42	41.45	7.83
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	4D Pharma PLC ADR (LBPS)	Silence Therapeutics PLC (SLN)	OKYO Pharma Ltd ADR (OKYO)
ROCE (%)	-86.03	-436.36	-126.47
ROE (%)	-105.78	-448.22	-129.51
ROA (%)	-67.80	-43.27	-87.24
EBIT Margin (%)	--	--	--
Net Margin (%)	-4,448.19	-317.44	--
Cash Profit Margin (%)	--	--	--

Growth Ratios

	4D Pharma PLC ADR (LBPS)	Silence Therapeutics PLC (SLN)	OKYO Pharma Ltd ADR (OKYO)
Revenue Growth (%)	0.34	1.27	--
EBIT Growth (%)	--	--	--
Net Profit Growth (%)	-23.01	-21.09	-117.49
EPS Growth (%)	--	-0.18	-1.01
Book Value Growth (%)	--	--	--

Valuation Ratios

	4D Pharma PLC ADR (LBPS)	Silence Therapeutics PLC (SLN)	OKYO Pharma Ltd ADR (OKYO)
Price / Earnings	--	-17.97	--
Price / Book Value	--	83.08	--
Dividend Yield (%)	--	--	--
EV/EBITDA	0.27	-13.98	--
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	4D Pharma PLC ADR (LBPS)	Silence Therapeutics PLC (SLN)	OKYO Pharma Ltd ADR (OKYO)
Debt to Equity	0.39	0.02	0.02
Short term debt to equity ratio	0.00	0.02	0.01
Current Ratio	5.21	5.69	4.09
Quick Ratio	5.16	5.69	4.09
Interest Coverage	--	-5,731.00	-3,681.07

Operating Efficiency Ratios

	4D Pharma PLC ADR (LBPS)	Silence Therapeutics PLC (SLN)	OKYO Pharma Ltd ADR (OKYO)
Debtors to sales (%)	407.33	2.67	--
Asset Turnover	0.02	0.14	0.00
Receivable days	2,285.78	435.96	--
Inventory Days	--	36.54	-0.17
Payable days	--	155.53	181.10
Cash Conversion Cycle	--	316.97	--

Annual
Quarterly